KD6001

DRUG2 trials

Sponsors

Shanghai Kanda Biotechnology Co., Ltd.

Conditions

Advanced HCCMelanomaOther Solid Tumors

Phase 1

KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma

Shanghai Kanda Biotechnology Co., Ltd.Melanoma

Start: 2023-03-22End: 2025-12-31Target: 84Updated: 2023-04-27

KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors

Shanghai Kanda Biotechnology Co., Ltd.Advanced HCC, Other Solid Tumors

Start: 2024-04-15End: 2025-12-31Target: 85Updated: 2024-01-10

Related Papers

A phase I/II study of KD6001, a novel fully human anti-CTLA4 IgG1 monoclonal antibody, in combination with toripalimab in patients with advanced melanoma.

Journal of Clinical Oncology2024-06-012 citations